1-2 of 2
Llorens Font
Close
Save search
Sort by
Journal Articles

Germline Polymorphisms Provide Strong Prognostic Information in Intermediate Risk Acute Myeloblastic Leukemia (AML).

Free
Alvaro Urbano-Ispizua, MD, Salut Brunet, MD, Mariano Monzo, MD, PhD, Granada Perea, MD, Alfons Navarro, PhD, Jordi Esteve, MD, Juan Berlanga, MD, Josep-Maria Ribera, MD, Javier Bueno, MD, Andreu Llorente, MD, Juan Besalduch, MD, Ramon Guardia, MD, Mar Tormo, MD, Carmen Pedro, MD, Juan-Maria Sanchez, MD, Pio Torres, MD, Maria-Paz Queipo de Llano, MD, Llorens Font, MD, Jose-Maria Moraleda, MD, Josep-Maria Marti, MD, Pilar Vivancos, MD, Maria-Jesus Peñarubia, MD, Josep Nomdedeu, MD, Emili Montserrat, MD, Jorge Sierra, MD
Journal: Blood
Blood (2004) 104 (11): 398.
https://doi.org/10.1182/blood.V104.11.398.398
Published: 2004
Journal Articles

Minimal Residual Disease (MRD) Analysis in Acute Myeloid Leukemia (AML) with Favorable Cytogenetics [t(8;21) and inv(16)] by Real Time PCR(RT-PCR) and Flow Cytometry (FC).

Free
Granada Perea, MD, Adriana Lasa, PhD, Anna Aventin, MD, Alicia Domingo, MD, Neus Villamor, MD, Maria Paz Queipo de LLano, MD, Andreu Llorente, MD, Jordi Junca, MD, Carlos Palacios, MD, Cristalina Fernandez, MD, Miquel Guallart, MD, Llorens Font, MD, Mar Tormo, MD, Lourdes Florensa, MD, Joan Bargay, MD, Josep M. Marti, MD, Pilar Vivancos, MD, Pio Torres, MD, Juan Berlanga, MD, Salut Brunet, MD, Jorge Sierra, MD, Josep F. Nomdedeu, MD
Journal: Blood
Blood (2004) 104 (11): 2989.
https://doi.org/10.1182/blood.V104.11.2989.2989
Published: 2004